point taken, and agree that there is a low chance of it making it in the AHA this year.
the focus is clearly on Ryoncil and COVID... we only need to look at how much content is given on these two in the recent announcements... and the two phase 3 trials get a sentence or two at best.
one thing is for sure though, they have the raw data and know the top line results... the detailed analysis is still in the works, but we simply don’t know the real reason for the hold up.
is it really the work load, or are they trying to time the release of news to minimise the impact on the share price?
I have said before that if the results are delayed to Dec or 21Q1, then I would lean toward the latter. But that’s just one persons opinion.
Phase 3 DREAM HF-1 read-out, page-129
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.010(1.09%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 94.0¢ | 89.5¢ | $4.970M | 5.436M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18877 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 6795 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |